ArticleDiscover oncology2026
Role of SERPINA1 in the tumor immune microenvironment of breast cancer and construction of a prognostic model.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBreast cancer is a common malignancy where the immune system plays a key role in disease progression and treatment response. SERPINA1 is an immune-related gene, but its function in breast cancer remains unclear. This study explored the expression, immune role, and prognostic value of SERPINA1 in breast cancer.
methodsWe analyzed data from TCGA and other public databases to evaluate SERPINA1 expression and performed Western blot and qPCR experiments for validation. Various bioinformatics tools were used to assess immune-related functions, identify differentially expressed genes, conduct pathway enrichment analyses, and construct a prognostic risk model. External datasets were used for validation, and immune activity and drug sensitivity were compared between different risk groups.
resultsSERPINA1 was significantly overexpressed in breast cancer tissues compared to normal tissues, and high expression was associated with better overall survival. High SERPINA1 expression correlated with enhanced activation of immune-related pathways, such as T and B-cell signaling. Patients with high SERPINA1 levels showed higher immune and stromal scores, increased infiltration of CD8⁺ T cells, macrophages, and dendritic cells, and elevated expression of immune checkpoint molecules. A prognostic model based on SERPINA1-associated immune genes effectively stratified patient survival risk and was validated in multiple external datasets. Patients in the low-risk group had stronger immune activity and were more sensitive to various chemotherapy and targeted drugs, suggesting the model’s potential in guiding personalized treatment.
conclusionSERPINA1 is closely linked to favorable prognosis and an active immune microenvironment in breast cancer. The SERPINA1-based prognostic model may be useful for survival prediction and personalized immunotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.